News

COVID-19.info

Popularization of research advances on COVID-19

Vaccines

Vaccination and cancer patients

Independent clinical trials have shown that the Pfizer and Moderna mRNA vaccines give 94-95% protection against symptomatic forms of COVID-19. But immunocompromised patients, who in general develop a less robust immune response, were not included in these trials. However, amongst this group there are patients with cancer who are treated with chemotherapy and whose care […]

Read more...

Immune markers that indicate good vaccination protection

Seventeen months after SARS-CoV-2 was identified, 6 vaccines against COVID-19 were already available. These vaccines give effective protection against serious illness and death. They reduce asymptomatic infection and limit the spread of the virus. However, supply of vaccines is still limited despite huge production efforts. It is therefore important that other vaccines be made available. […]

Read more...

Vaccinal nationalism : solution or pipe dream?

In certain countries, the deployment of safe and effective vaccines has enabled a reduction in numbers of cases, hospitalisations and deaths due to COVID-19. The possible need for a third dose, to compensate for a potential weakening of immunity or to increase protection against certain variants, has encouraged “vaccine nationalism”, that is, where countries stock-pile […]

Read more...

A small dose of Moderna is enough to activate an immune-memory response

Infection by SARS-CoV-2 and vaccination are 2 ways of acquiring protective immunity. After infection, an immune-memory response remains active for at least 8 months, deploying antibodies along with CD4 and CD8 T lymphocytes. Pfizer-BioNTech and Moderna, mRNA vaccines have proved very effective in preventing serious cases of COVID-19. In clinical trials of Moderna, 2 doses […]

Read more...

Will a future vaccine using nanoparticles be effective against several coronaviruses?

The various epidemics of Sarbecoviruses, coronaviruses originating from bats (SARS-CoV-2, SARS-CoV and MERS-CoV) suggest that we are not safe from future outbreaks.  In addition, SARS-CoV-2 variants such as the Alpha (UK), Beta (South African) and Delta (Indian) variants are able to partially evade the antibodies activated by vaccination. It is in this context that American […]

Read more...

The effectiveness of vaccines against variants

In August 2021, the World Health Organisation (WHO) designated 4 variants as “of concern” (Variants of Concern, VOC): the Alpha/UK, the Beta/South African, the Gamma/Brazilian and the Delta/Indian variants. This classification was based on their abilities to spread and to escape immune responses, and on their virulence. Amongst the 21 vaccines that have been urgently […]

Read more...

The protective mechanisms of Moderna – a study using macaques

Mass vaccination against SARS-CoV-2 is the best means we have of controlling the COVID-19 pandemic. The Moderna and Pfizer mRNA vaccines, which are based on immunity created by targeting the spike protein which governs the entry of the virus into the cell, have been shown to be more than 94% effective in preventing symptomatic cases. […]

Read more...
Read more...

A broad-spectrum vaccine effective against sarbecovirus

SARS-CoV-2 is a member of the genus β-coronavirus and subgenus sarbecovirus. Other sarbecoviruses have already caused epidemics, such as SARS-CoV in 2003 (about 8 000 infections and 800 deaths) and MERS-CoV in 2012 (at least 2 600 cases and 900 deaths). Sarbecoviruses have spike surface proteins, the target of powerful neutralising antibodies, that differ while […]

Read more...

Targeting epitopes to improve vaccines

Obtaining a vaccine that works against COVID-19 has been one of the main priorities of recent times. Numerous candidate vaccines, using different technological platforms, have been developed. These vaccines, designed by expressing the SARS-CoV-2 spike surface protein, induce neutralising antibodies against this virus. However, the emergence of variants such as Alpha or Delta, that have […]

Read more...
error: Content is protected !!